# Longitudinal study on the epidemiology and management of auto-immune thrombocytopenia (AITP) in Algeria

First published: 08/09/2017 Last updated: 23/04/2024





# Administrative details

PURI https://redirect.ema.europa.eu/resource/36269
EU PAS number
EUPAS20687
Study ID
36269
DARWIN EU® study
No
Study countries  Algeria

## **Study description**

Epidemiological, national, prospective, longitudinal study about the management of patients with auto-immune thrombocytopenia followed up by hematologists in the public sector in Algeria.

## **Study status**

**Finalised** 

# Research institutions and networks

## Institutions

# Amgen

United States

First published: 01/02/2024

Last updated: 21/02/2024

Institution

Multiple centres: 16 centres are involved in the study

## Contact details

**Study institution contact** 

## Global Development Leader Amgen Inc.

Study contact

medinfo@amgen.com

## **Primary lead investigator**

Global Development Leader Amgen Inc.

Primary lead investigator

# Study timelines

## Date when funding contract was signed

Planned: 07/04/2017

Actual: 07/07/2017

## Study start date

Planned: 08/09/2017 Actual: 08/09/2017

#### Data analysis start date

Planned: 31/07/2019 Actual: 14/07/2019

#### **Date of final study report**

Planned: 30/06/2020 Actual: 09/07/2020

# Sources of funding

• Pharmaceutical company and other private sector

# More details on funding

Amgen

# Study protocol

20160214\_01.02.06 Public Redacted Protocol Ver 1.0 2018-07-28 English.pdf (557.28 KB)

# Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Methodological aspects

Study type

Study type list

**Study topic:** 

Disease /health condition

#### Study type:

Non-interventional study

#### Scope of the study:

Disease epidemiology

#### **Data collection methods:**

Combined primary data collection and secondary use of data

#### Main study objective:

To assess the incidence of AITP diagnosed in patients aged 16 years old and over in Algeria in a 12-month period of inclusion

# Study Design

## Non-interventional study design

Other

## Non-interventional study design, other

Longitudinal prospective epidemiological study

# Study drug and medical condition

#### Medical condition to be studied

Immune thrombocytopenia

# Population studied

#### Short description of the study population

All patients over 16 years old previously diagnosed (prior to inclusion visit) or newly diagnosed (at the time of the inclusion visit) with AITP, treated in the hematology departments in Algeria and who gave their informed consent, were included in the study.

#### **Age groups**

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

#### **Special population of interest**

Other

#### Special population of interest, other

Immune thrombocytopenic purpura patients

#### **Estimated number of subjects**

200

# Study design details

#### **Outcomes**

Number of new cases diagnosed with AITP and aged 16 years and over, in Algeria during the period of 12 months of inclusion. Number of new cases diagnosed with AITP and aged 16 years and over, during the period of 12

months of inclusion, by age categories. Number diagnosed with AITP and aged 16 years and over, in Algeria during the period of 12 months of inclusion, by gender, diagnosis stage, Wilaya.

#### **Data analysis plan**

This study is an estimation study, so no formal statistical testing will be performed. A descriptive analysis of the collected variables will be conducted.

## **Documents**

#### Study results

20160214 AITP CSR 24JULY2019 Final (002) Redacted.pdf(261.64 KB)

# Data management

## Data sources

## **Data sources (types)**

Disease registry

Drug dispensing/prescription data

Electronic healthcare records (EHR)

Other

## Data sources (types), other

Prospective patient-based data collection, Prescription event monitoring

# Use of a Common Data Model (CDM)

## **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

## **Check completeness**

Unknown

## **Check stability**

Unknown

## **Check logical consistency**

Unknown

## Data characterisation

#### **Data characterisation conducted**

No